Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2018-10-16 | GLYC | Glycomimetics Inc | Magnani John L. | SVP of Research, CSO | S - Sale | $14.01 | -25,000 | 80,638 | -24% | -$350,213 | |||||
| D | 2018-08-13 | CERC | Cerecor Inc. | Jones Randal | 10% | S - Sale+OE | $3.98 | -1,270 | 0 | -100% | -$5,055 | |||||
| M | 2018-10-16 | ESPR | Esperion Therapeutics, Inc. | Newton Roger S | Dir | S - Sale | $50.02 | -22,173 | 576,553 | -4% | -$1,108,997 | |||||
2018-10-16 | FLKS | Flex Pharma, Inc. | Longwood Fund Ii, L.P. | 10% | S - Sale | $0.92 | -3,212,861 | 0 | -100% | -$2,941,053 | ||||||
2018-10-16 | CCXI | Chemocentryx, Inc. | Glaxosmithkline Plc | Former 10% holder | S - Sale | $11.69 | -7,343,492 | 0 | -100% | -$85,845,421 | ||||||
2018-10-16 | FLKS | Flex Pharma, Inc. | Westphal Christoph H | 10% | S - Sale | $0.92 | -3,212,861 | 3,941,118 | -45% | -$2,941,053 | ||||||
2018-10-18 | SNGX | Soligenix, Inc. | Schaber Christopher J | COB, CEO, Pres | P - Purchase | $1.17 | +8,700 | 37,325 | +30% | +$10,177 | ||||||
2018-10-16 | MSLP | Musclepharm Corp | Wynnefield Partners Small Cap Value LP I | 10% | P - Purchase | $1.00 | +15,000 | 1,671,305 | +1% | +$15,000 | ||||||
2018-10-17 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $113.25 | -174,696 | 119,005,804 | 0% | -$19,783,623 | ||||||
| D | 2018-10-16 | CTLT | Catalent, Inc. | Miyamoto Lance | SVP, HR | S - Sale+OE | $42.50 | -6,525 | 46,799 | -12% | -$277,313 | |||||
2018-10-15 | IMMY | Imprimis Pharmaceuticals, Inc. | Kammer Robert J | Dir | S - Sale | $3.00 | -10,000 | 909,827 | -1% | -$30,000 | ||||||
2018-10-17 | SNGX | Soligenix, Inc. | Pearson Mark E. | Dir | P - Purchase | $1.16 | +170,000 | 2,500,000 | +7% | +$197,200 | ||||||
| D | 2018-10-15 | FOLD | Amicus Therapeutics Inc | Baird William D III | CFO | S - Sale+OE | $12.23 | -10,000 | 117,622 | -8% | -$122,275 | |||||
| A | 2018-07-02 | FOLD | Amicus Therapeutics Inc | Baird William D III | CFO | S - Sale | $15.63 | -10,000 | 117,622 | -8% | -$156,292 | |||||
| D | 2018-10-15 | ALLO | Allogene Therapeutics, Inc. | Pfizer Inc | 10% | P - Purchase | $18.00 | +55,556 | 22,032,040 | 0% | +$1,000,008 | |||||
2018-10-15 | CALA | Calithera Biosciences, Inc. | Orford Keith | SVP, CLINICAL DEVELOPMENT | S - Sale | $6.05 | -313 | 10,314 | -3% | -$1,894 | ||||||
2018-10-15 | JAZZ | Jazz Pharmaceuticals Plc | Young Matthew P. | EVP, CFO | S - Sale | $158.08 | -700 | 32,768 | -2% | -$110,658 | ||||||
2018-10-15 | COLL | Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Dir | S - Sale | $16.53 | -25,000 | 361,000 | -6% | -$413,250 | ||||||
| DM | 2018-10-15 | EBS | Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | S - Sale+OE | $61.06 | -22,996 | 29,253 | -44% | -$1,404,026 | |||||
| M | 2018-10-15 | BHC | Bausch Health Companies Inc. | Ackermann Christina | EVP, GC | S - Sale | $24.98 | -19,946 | 51,456 | -28% | -$498,302 | |||||
| D | 2018-10-15 | CTLT | Catalent, Inc. | Littlejohns Barry | Pres, Biologics, SDD | S - Sale+OE | $41.64 | -47,265 | 37,718 | -56% | -$1,968,115 | |||||
2018-10-16 | IMGN | Immunogen Inc | Berkenblit Anna | VP, Chief Medical Officer | S - Sale | $8.00 | -5,851 | 132,769 | -4% | -$46,808 | ||||||
2018-10-15 | PRTK | Paratek Pharmaceuticals, Inc. | Bigham Michael | COB, CEO | S - Sale | $8.96 | -6,300 | 264,867 | -2% | -$56,448 | ||||||
2018-10-15 | PRTK | Paratek Pharmaceuticals, Inc. | Pagan Douglas W. | CFO | S - Sale | $8.96 | -2,784 | 123,220 | -2% | -$24,945 | ||||||
2018-10-15 | PRTK | Paratek Pharmaceuticals, Inc. | Haskel William M. | SVP, Sec., GC | S - Sale | $8.96 | -2,231 | 102,683 | -2% | -$19,990 | ||||||
2018-10-15 | PRTK | Paratek Pharmaceuticals, Inc. | Loh Evan | Pres, COO, CMO | S - Sale | $8.96 | -5,200 | 289,225 | -2% | -$46,592 | ||||||
2018-10-15 | PRTK | Paratek Pharmaceuticals, Inc. | Woodrow Adam | VP, Chief Commercial Officer | S - Sale | $8.96 | -2,659 | 135,508 | -2% | -$23,825 | ||||||
| D | 2018-10-15 | ICPT | Intercept Pharmaceuticals, Inc. | Shapiro David | Chief Medical Officer | S - Sale+OE | $102.95 | -3,425 | 39,152 | -8% | -$352,604 | |||||
2018-10-12 | RIGL | Rigel Pharmaceuticals Inc | Cabatuan Nelson | Principal Accounting Officer | S - Sale | $3.12 | -10,000 | 58 | -99% | -$31,200 | ||||||
| M | 2018-10-09 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.05 | +18,000 | 26,028,898 | 0% | +$888 | |||||
2018-10-15 | ACRX | Acelrx Pharmaceuticals Inc | Hamel Lawrence G | Chief Development Officer | S - Sale | $5.00 | -5,216 | 54,166 | -9% | -$26,080 | ||||||
2018-10-15 | ACRX | Acelrx Pharmaceuticals Inc | Dasu Badri N | Chief Engineering Officer | S - Sale | $5.00 | -28,351 | 54,061 | -34% | -$141,755 | ||||||
| D | 2018-10-12 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale+OE | $177.20 | -2,125 | 39,609 | -5% | -$376,550 | |||||
2018-10-12 | JAZZ | Jazz Pharmaceuticals Plc | Miller Michael Patrick | EVP, US Commercial | S - Sale | $158.46 | -200 | 25,172 | -1% | -$31,692 | ||||||
| A | 2018-10-05 | ECYT | Endocyte Inc | Low Philip S | Chief Science Officer | S - Sale | $15.56 | -5,928 | 506,535 | -1% | -$92,238 | |||||
| A | 2018-10-05 | ECYT | Endocyte Inc | Parker Katherine | VP of HR | S - Sale | $15.55 | -6,771 | 72,069 | -9% | -$105,316 | |||||
| A | 2018-10-05 | ECYT | Endocyte Inc | Leamon Christopher P | VP of Research | S - Sale | $15.56 | -9,028 | 122,219 | -7% | -$140,437 | |||||
2018-10-15 | MCRB | Seres Therapeutics, Inc. | Aunins John G. | See Remarks | S - Sale | $5.94 | -14,279 | 103,811 | -12% | -$84,800 | ||||||
2018-10-15 | CBAY | Cymabay Therapeutics, Inc. | Shah Sujal | CEO | P - Purchase | $9.90 | +5,000 | 100,000 | +5% | +$49,500 | ||||||
| DM | 2018-10-11 | TXMD | Therapeuticsmd, Inc. | Finizio Robert G | CEO | S - Sale+OE | $5.55 | -184,000 | 20,393,559 | -1% | -$1,020,832 | |||||
| D | 2018-10-15 | GTHX | G1 Therapeutics, Inc. | Malik Rajesh | Ch. Medical Officer, SVP R, D | S - Sale+OE | $41.71 | -3,776 | 14,700 | -20% | -$157,497 | |||||
| D | 2018-10-15 | GTHX | G1 Therapeutics, Inc. | Velleca Mark A. | Pres, CEO | S - Sale+OE | $41.53 | -5,000 | 19,000 | -21% | -$207,645 | |||||
| D | 2018-10-15 | ATNX | Athenex, Inc. | Wu Jinn | Dir | P - Purchase | $13.47 | +12,500 | 311,208 | +4% | +$168,375 | |||||
2018-10-11 | CALA | Calithera Biosciences, Inc. | Orford Keith | SVP, CLINICAL DEVELOPMENT | S - Sale | $6.00 | -1,252 | 10,627 | -11% | -$7,512 | ||||||
| M | 2018-10-11 | CORI | Corium International, Inc. | Perceptive Advisors LLC | 10% | S - Sale | $12.52 | -3,632,447 | 2,724,686 | -57% | -$45,460,412 | |||||
2018-10-11 | NERV | Minerva Neurosciences, Inc. | Doyle William F | Dir | P - Purchase | $10.00 | +600 | 12,611 | +5% | +$6,000 | ||||||
| M | 2018-10-11 | KMPH | Kempharm, Inc | Sangiovanni Timothy J. | VP, Corporate Controller | P - Purchase | $2.52 | +3,000 | 3,000 | New | +$7,575 | |||||
2018-10-12 | SBOT | Stellar Biotechnologies, Inc. | Morse Daniel E. | Former Director | S - Sale | $1.31 | -7,047 | 20,741 | -25% | -$9,260 | ||||||
2018-10-12 | SBOT | Stellar Biotechnologies, Inc. | Oakes Frank R. | Pres, CEO | S - Sale | $1.31 | -3,000 | 51,924 | -5% | -$3,930 | ||||||
| M | 2018-10-10 | BPMX | Biopharmx Corp | Krammer Anja B | Dir | S - Sale | $0.19 | -500,000 | 2,000,000 | -20% | -$95,000 | |||||
2018-10-12 | KMPH | Kempharm, Inc | Mickle Travis C | Pres, CEO, 10% | P - Purchase | $2.55 | +5,000 | 2,400,145 | 0% | +$12,764 | ||||||
| M | 2018-10-10 | KMPH | Kempharm, Inc | Johnson Gordon K | Chief Business Officer | P - Purchase | $2.61 | +4,000 | 10,000 | +67% | +$10,457 | |||||
2018-10-09 | SPPI | Spectrum Pharmaceuticals Inc | Gagnon Gilles | Dir | S - Sale | $15.33 | -10,000 | 72,500 | -12% | -$153,349 | ||||||
| DM | 2018-10-09 | TXMD | Therapeuticsmd, Inc. | Milligan John C.K. IV | Pres, Secretary | S - Sale+OE | $5.85 | -250,000 | 5,464,606 | -4% | -$1,462,750 | |||||
2018-10-10 | OMED | Oncomed Pharmaceuticals Inc | Stagg Robert | SVP, Clinical R, D | S - Sale | $2.01 | -927 | 40,670 | -2% | -$1,863 | ||||||
2018-10-10 | OMED | Oncomed Pharmaceuticals Inc | Li Yvonne | See Remarks | S - Sale | $2.02 | -927 | 59,734 | -2% | -$1,873 | ||||||
2018-10-10 | OMED | Oncomed Pharmaceuticals Inc | Gurney Austin | See Remarks | S - Sale | $2.01 | -1,156 | 77,924 | -1% | -$2,324 | ||||||
2018-10-10 | OMED | Oncomed Pharmaceuticals Inc | Hager Alicia J. | SVP, GC | S - Sale | $2.02 | -1,156 | 51,754 | -2% | -$2,335 | ||||||
2018-10-10 | OMED | Oncomed Pharmaceuticals Inc | Lewicki John A. | Pres, CEO | S - Sale | $2.01 | -1,156 | 155,354 | -1% | -$2,324 | ||||||
2018-10-11 | KMPH | Kempharm, Inc | Clifton R. Laduane | CFO, Secretary, Treasurer | P - Purchase | $2.54 | +650 | 2,750 | +31% | +$1,652 | ||||||
2018-10-09 | ALT | Altimmune, Inc. | Pisano Wayne | Dir | P - Purchase | $4.59 | +2,000 | 2,000 | New | +$9,180 | ||||||
2018-10-09 | OMED | Oncomed Pharmaceuticals Inc | Li Yvonne | See Remarks | S - Sale | $2.13 | -1,229 | 60,661 | -2% | -$2,616 | ||||||
2018-10-09 | OMED | Oncomed Pharmaceuticals Inc | Gurney Austin | See Remarks | S - Sale | $2.13 | -1,686 | 79,080 | -2% | -$3,589 | ||||||
2018-10-09 | OMED | Oncomed Pharmaceuticals Inc | Stagg Robert | SVP, Clinical R, D | S - Sale | $2.13 | -1,686 | 41,597 | -4% | -$3,589 | ||||||
2018-10-09 | OMED | Oncomed Pharmaceuticals Inc | Lewicki John A. | Pres, CEO | S - Sale | $2.13 | -2,296 | 156,510 | -1% | -$4,888 | ||||||
2018-10-09 | OMED | Oncomed Pharmaceuticals Inc | Hager Alicia J. | SVP, GC | S - Sale | $2.13 | -1,686 | 52,910 | -3% | -$3,589 | ||||||
| D | 2018-10-08 | GTHX | G1 Therapeutics, Inc. | Moses Jennifer K. | VP of Finance, Admin | S - Sale+OE | $44.52 | -750 | 2,000 | -27% | -$33,390 | |||||
2018-10-09 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $115.91 | -10,672 | 119,180,500 | 0% | -$1,237,013 | ||||||
| DM | 2018-10-04 | TXMD | Therapeuticsmd, Inc. | Bernick Brian | Dir | S - Sale+OE | $5.91 | -182,800 | 6,802,371 | -3% | -$1,080,348 | |||||
| DM | 2018-10-04 | IRWD | Ironwood Pharmaceuticals Inc | Currie Mark G | Chief Scientific Officer | S - Sale+OE | $17.81 | -233,301 | 805,124 | -22% | -$4,155,570 | |||||
| D | 2018-10-04 | ZGNX | Zogenix, Inc. | Farfel Gail M | EVP, Chief Development Officer | S - Sale+OE | $43.23 | -6,961 | 7,143 | -49% | -$300,928 | |||||
| M | 2018-10-05 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.05 | +17,000 | 26,010,898 | 0% | +$872 | |||||
| DM | 2018-10-04 | CERC | Cerecor Inc. | Armistice Capital, LLC | Dir, 10% | P - Purchase | $4.34 | +29,600 | 35,060,000 | 0% | +$128,405 | |||||
| D | 2018-10-08 | CORT | Corcept Therapeutics Inc | Fishman Robert S | Chief Medical Officer | S - Sale+OE | $13.19 | -8,000 | 0 | -100% | -$105,538 | |||||
2018-10-08 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | EVP, CMO | S - Sale | $186.95 | -2,305 | 1,909 | -55% | -$430,920 | ||||||
2018-10-05 | KALA | Kala Pharmaceuticals, Inc. | Grunberg Gregory | Dir | P - Purchase | $8.25 | +606,060 | 2,877,006 | +27% | +$4,999,995 | ||||||
| DM | 2015-05-12 | RARE | Ultragenyx Pharmaceutical Inc. | Aliski William | Dir | S - Sale+OE | $72.49 | -19,550 | 283,310 | -6% | -$1,417,098 | |||||
| AD | 2018-08-21 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale+OE | $78.53 | -5,000 | 14,181 | -26% | -$392,650 | |||||
2018-10-08 | LGND | Ligand Pharmaceuticals Inc | Davis Todd C | Dir | S - Sale | $253.99 | -2,500 | 42,556 | -6% | -$634,978 | ||||||
| D | 2018-10-05 | AGIO | Agios Pharmaceuticals Inc | Biller Scott | Chief Scientific Officer | S - Sale+OE | $69.79 | -3,000 | 57,196 | -5% | -$209,377 | |||||
2018-10-05 | KMPH | Kempharm, Inc | Delaware Street Capital Master Fund, L.P. | 10% | P - Purchase | $3.00 | +2,000,000 | 4,095,914 | +95% | +$6,000,000 | ||||||
2018-10-05 | ECYT | Endocyte Inc | Armour Alison A. | Chief Medical Officer | S - Sale | $15.56 | -9,111 | 101,040 | -8% | -$141,748 | ||||||
2018-10-05 | ECYT | Endocyte Inc | Leamon Christopher P | VP of Research | S - Sale | $15.56 | -9,028 | 121,353 | -7% | -$140,437 | ||||||
2018-10-05 | ECYT | Endocyte Inc | Taylor Beth | VP Finance, Chief Acctg Offcr | S - Sale | $15.56 | -7,022 | 56,341 | -11% | -$109,287 | ||||||
2018-10-05 | ECYT | Endocyte Inc | Sherman Michael A. | Pres, CEO | S - Sale | $15.55 | -28,146 | 367,837 | -7% | -$437,752 | ||||||
| M | 2018-10-05 | ECYT | Endocyte Inc | Andriole Michael T. | CFO | S - Sale | $15.56 | -17,918 | 132,082 | -12% | -$278,848 | |||||
2018-10-05 | ECYT | Endocyte Inc | Chelius Erik C. | VP CMC | S - Sale | $15.56 | -4,514 | 49,895 | -8% | -$70,243 | ||||||
2018-10-05 | ECYT | Endocyte Inc | Parker Katherine | VP of HR | S - Sale | $15.55 | -6,771 | 71,549 | -9% | -$105,316 | ||||||
2018-10-05 | ECYT | Endocyte Inc | Low Philip S | Chief Science Officer | S - Sale | $15.56 | -5,928 | 504,802 | -1% | -$92,238 | ||||||
2018-10-08 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $115.91 | -14,632 | 119,191,172 | 0% | -$1,696,039 | ||||||
| D | 2018-10-08 | KPTI | Karyopharm Therapeutics Inc. | Kauffman Michael | CEO | S - Sale+OE | $15.75 | -12,500 | 1,320,271 | -1% | -$196,832 | |||||
| D | 2018-10-08 | KPTI | Karyopharm Therapeutics Inc. | Shacham Sharon | Pres, CSO | S - Sale+OE | $15.75 | -12,500 | 1,320,271 | -1% | -$196,832 | |||||
| D | 2018-10-04 | MYOK | Myokardia Inc | Gianakakos Anastasios | Pres, CEO | S - Sale+OE | $58.19 | -3,000 | 697,522 | 0% | -$174,578 | |||||
2018-10-05 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $8.79 | -4,000 | 164,188 | -2% | -$35,178 | ||||||
2018-10-05 | ICPT | Intercept Pharmaceuticals, Inc. | Shapiro David | Chief Medical Officer | S - Sale | $110.65 | -759 | 39,152 | -2% | -$83,983 | ||||||
2018-10-05 | EPZM | Epizyme, Inc. | Mott David M | Dir | P - Purchase | $9.00 | +416,667 | 6,890,257 | +6% | +$3,750,003 | ||||||
| D | 2018-10-04 | GTHX | G1 Therapeutics, Inc. | Rudnick Seth | Dir | S - Sale+OE | $49.72 | -10,000 | 58,282 | -15% | -$497,210 | |||||
| D | 2018-10-03 | GTHX | G1 Therapeutics, Inc. | Murdock Terry L | SVP of Development Operations | S - Sale+OE | $49.18 | -3,519 | 0 | -100% | -$173,064 | |||||
2018-10-03 | BMRN | Biomarin Pharmaceutical Inc | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | S - Sale | $98.98 | -1,000 | 49,135 | -2% | -$98,985 | ||||||
2018-10-03 | PTIE | Pain Therapeutics Inc | Armistice Capital, LLC | 10% | S - Sale | $1.31 | -512,660 | 1,651,340 | -24% | -$671,738 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |